# Biobot Analytics **Source:** https://geo.sig.ai/brands/biobot-analytics **Vertical:** Government Tech **Subcategory:** Public Health Surveillance **Tier:** Challenger **Website:** biobot.io **Last Updated:** 2026-04-14 ## Summary Biobot Analytics is a wastewater epidemiology company that analyzes sewage to track infectious diseases, substance use, and public health trends across communities. HQ: Cambridge, MA. ## Company Overview Biobot Analytics is a public health infrastructure company that uses wastewater epidemiology to provide early warning of infectious disease outbreaks, substance use trends, and other public health indicators to communities, public health agencies, and the federal government. Founded in 2017 by MIT graduates Mariana Matus and Newsha Ghaeli, the company became nationally prominent during the COVID-19 pandemic when its wastewater surveillance network provided some of the earliest data on SARS-CoV-2 spread in communities — often detecting outbreaks 4–7 days before clinical case reports. Biobot operates the nation's largest wastewater disease surveillance network, processing samples from hundreds of wastewater treatment plants across all 50 states. The company's scientific methodology involves extracting and concentrating pathogen genetic material (RNA or DNA) from wastewater influent, then applying qPCR and sequencing techniques to quantify pathogen concentrations and identify variants. These measurements provide population-level health intelligence that is fundamentally different from individual clinical testing: wastewater captures signal from asymptomatic individuals, people who don't seek testing, and entire communities simultaneously. Beyond COVID-19, Biobot's platform tracks influenza, RSV, mpox, emerging variants, and illicit drug metabolites (tracking fentanyl and other opioid use at the community level). The CDC has partnered with Biobot as a core component of the National Wastewater Surveillance System (NWSS) established during the pandemic — institutionalizing wastewater epidemiology as a permanent public health monitoring tool. Biobot has raised $30M+ in venture funding and revenue from government contracts, public health agencies, and increasingly, pharmaceutical companies seeking real-world disease prevalence data. ## Frequently Asked Questions ### What does Biobot Analytics do? Biobot analyzes wastewater samples from hundreds of treatment plants to track infectious diseases (COVID, flu, RSV), opioid use, and public health trends at the community level — providing earlier and broader disease surveillance than individual clinical testing. ### Why is wastewater epidemiology valuable? Wastewater captures health signals from the entire population served by a sewer system, including asymptomatic individuals and people who never seek testing. It provides earlier outbreak detection (typically 4–7 days ahead of clinical reports) and population-level prevalence data without individual testing bias. ### How did Biobot grow during COVID-19? Biobot became a critical component of U.S. COVID-19 surveillance, expanding from a few cities to hundreds of treatment plants by 2021–2022. The CDC formally incorporated wastewater surveillance into national public health infrastructure through the National Wastewater Surveillance System (NWSS), with Biobot as a key partner. ### Who uses Biobot's data? Public health agencies (local, state, federal), the CDC, hospitals, emergency preparedness teams, and pharmaceutical companies use Biobot's wastewater data to track disease burden, prepare healthcare capacity, guide public health interventions, and understand real-world disease prevalence. ### What diseases beyond COVID does Biobot track? Biobot has expanded from COVID-19 surveillance to tracking influenza, RSV, norovirus, West Nile virus, and opioid metabolites including fentanyl and xylazine — building a comprehensive community health intelligence platform from wastewater. ### Is Biobot publicly traded? No, Biobot Analytics is a privately held public health technology company headquartered in Cambridge, Massachusetts, backed by investors including Y Combinator and Sequoia Capital. ### How does Biobot's opioid monitoring work? Biobot detects opioid metabolites in wastewater to estimate community-level drug use, providing public health departments and harm reduction organizations with early warning of fentanyl surges before overdose emergency department data reflects the trend. ### How quickly does wastewater data predict community disease burden? Wastewater data typically predicts clinical case rises 4-7 days earlier than positive test reports, giving public health officials a meaningful lead time to prepare healthcare capacity, issue public guidance, and deploy additional resources. ## Tags b2b, saas --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*